ViewTrade looks to AI for wealth management
As Aussie investors seek global exposure, ViewTrade uses AI to simplify cross-border investing and wealth management.
Content
QEM gets key government tick
QEM’s flagship vanadium and oil shale development has been declared a Coordinated Project by the Queensland Government.
Road to 2025: CC9
Sarah Hughan covers Chariot Corporation and a groundbreaking Wyoming discovery within the largest lithium exploration portfolio in the United States.
MTM Critical Metals placed to supply domestic US gallium
MTM Critical Metals completes an unsolicited and undiscounted $7.5m placement to commercialise unique gallium recovery tech.
Bailador on how AI could shape investing’s future
Bailador Technology Investments believes artificial intelligence will play an increasing role in growth equity investing as the tech continues to advance.
GT1 on Ontario lithium fast track
Export Development Canada could provide up to C$100 million to finance Green Technology Metals’ Seymour lithium project.
Road to 2025: RCE
Sarah Hughan explores Recce Pharmaceuticals and a series of successes advancing a new class of synthetic anti-infectives.
The year crypto went mainstream
The crypto market has entered a new era of growth and mainstream adoption, with 2024 representing a significant turning point, writes James Quinn-Kumar.
Copper explorer MHM lists on the ASX
Mount Hope Mining has already identified five priority exploration prospects at its project in NSW’s Cobar region for exploration in early 2025.
Lumos starts CLIA waiver study in US
Lumos has begun a crucial study in the US for its FebriDx point-of-care test to aid in differentiation between bacterial and non-bacterial acute respiratory infections.
Road to 2025: OCT
Sarah Hughan explores Octava Minerals and its advancement into an antimony market showing little slow down.
Comet Ridge’s Tor McCaul chats Queensland gas supply
Comet Ridge’s managing director Tor McCaul joins Sarah Hughan on Stockhead TV to talk about the company’s $12M capital raise for the Mahalo Gas project.
Geopacific raises $40m for 1.67 Moz Woodlark Gold Project
Geopacific Resources raises game-changing $40m to develop Woodlark Gold Project
Road to 2025: Kingsland Minerals
Sarah Hughan gravitates towards Kingsland Minerals and a gigantic graphite deposit being advanced to production.
FDA inspection of EBR’s WiSE CRT set for January
The US FDA has scheduled a pre-approval inspection of EBR System’s WiSE CRT System for the week of January 6, 2025.
Road to 2025: GRV
Greenvale Energy had a big 2024, acquiring an 80% stake in four uranium projects in the NT, advancing its Alpha Torbanite bitumen project and more.
OCC seeks US nod for nerve-repair product sales
Orthocell is well placed for the commercial launch of its Remplir nerve-repair device once clearance is received from the US Food and Drug Administration.
AZY raises $16m to advance Minyari Dome
Strong support for Antipa Minerals’ $16m placement validates its strategy and highlights its growth potential.
Nova set to unlock Estelle gold and antimony value in 2025
Nova Minerals is all set to unlock gold and antimony value at its large-scale Estelle gold and critical minerals project in Alaska.
LTR Pharma inks deal with men’s health provider
LTR Pharma has signed an access agreement with Mens Health Downunder to facilitate supply of Spontan, its novel nasal spray treatment for erectile dysfunction.
BlinkLab gains FDA support for trial
BlinkLab has received a positive outcome from a pre-submission meeting with the FDA on a regulatory pathway for its BlinkLab Dx 1 platform as an autism diagnosis aid.
Road to 2025: PRX
Sarah Hughan delves into Prodigy Gold and its advancement towards shovel-ready in its proven, yet underexplored end of the Tanami.
Neurizon gains EU orphan status for motor neurone drug
European Medicines Agency grants orphan drug designation for Neurizon’s lead drug candidate NUZ-001 to treat Amyotrophic Lateral Sclerosis.
Adisyn wraps up due diligence on 2DG
Adisyn’s acquisition of 2DG could help capture opportunities in the hot and emerging semiconductor market.
Positive interim results for Trytamine IBS trial
Tryptamine reports positive interim analysis for its phase 2a clinical study of oral psilocybin formula TRP-8802 in patients with IBS.
Original URL: https://www.theaustralian.com.au/business/stockhead/content